P. Fleck

6.0k total citations · 2 hit papers
38 papers, 4.7k citations indexed

About

P. Fleck is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, P. Fleck has authored 38 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Molecular Biology and 12 papers in Surgery. Recurrent topics in P. Fleck's work include Diabetes Treatment and Management (33 papers), Metabolism, Diabetes, and Cancer (12 papers) and Diabetes Management and Research (11 papers). P. Fleck is often cited by papers focused on Diabetes Treatment and Management (33 papers), Metabolism, Diabetes, and Cancer (12 papers) and Diabetes Management and Research (11 papers). P. Fleck collaborates with scholars based in United States, United Kingdom and France. P. Fleck's co-authors include Craig Wilson, Qais Mekki, William B. White, William C. Cushman, Cyrus R. Mehta, Christopher P. Cannon, George L. Bakris, Faı̈ez Zannad, Stuart Kupfer and Alfonso T. Perez and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

P. Fleck

37 papers receiving 4.5k citations

Hit Papers

Alogliptin after Acute Coronary Syndrome in Patients with... 2013 2026 2017 2021 2013 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
    2013 1.9k citations William B. White, Christopher P. Cannon et al. New England Journal of Medicine profile →
  2. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
    2015 551 citations Faı̈ez Zannad, Christopher P. Cannon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Fleck United States 27 4.3k 1.6k 1.5k 1.0k 699 38 4.7k
Peter P. Stein United States 22 4.3k 1.0× 1.8k 1.1× 1.7k 1.1× 833 0.8× 567 0.8× 27 4.9k
Hans‐Juergen Woerle Germany 32 4.1k 1.0× 1.6k 1.0× 1.9k 1.3× 652 0.6× 388 0.6× 61 4.4k
Peter Öhman United States 19 5.1k 1.2× 2.0k 1.2× 1.6k 1.1× 533 0.5× 1.1k 1.6× 32 5.6k
M. Angelyn Bethel United States 22 4.3k 1.0× 1.7k 1.0× 1.5k 1.0× 459 0.4× 1.0k 1.5× 39 5.1k
Craig Wilson United States 15 3.0k 0.7× 1.1k 0.7× 958 0.7× 630 0.6× 673 1.0× 28 3.3k
Alfonso T. Perez United States 7 2.8k 0.6× 1.3k 0.8× 882 0.6× 464 0.4× 676 1.0× 8 3.2k
Jennifer B. Green United States 31 3.6k 0.8× 1.4k 0.8× 1.3k 0.9× 474 0.5× 1.5k 2.2× 91 5.0k
Matthew A. Cavender United States 28 4.7k 1.1× 2.0k 1.2× 2.1k 1.4× 684 0.7× 2.3k 3.3× 86 6.7k
Stuart Kupfer United States 27 4.0k 0.9× 1.6k 1.0× 1.3k 0.9× 505 0.5× 2.3k 3.3× 82 5.6k
Richard M. Bergenstal United States 15 6.6k 1.5× 2.6k 1.6× 2.2k 1.5× 484 0.5× 1.5k 2.1× 29 7.6k

Countries citing papers authored by P. Fleck

Since Specialization
Citations

This map shows the geographic impact of P. Fleck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Fleck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Fleck more than expected).

Fields of papers citing papers by P. Fleck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Fleck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Fleck. The network helps show where P. Fleck may publish in the future.

Co-authorship network of co-authors of P. Fleck

This figure shows the co-authorship network connecting the top 25 collaborators of P. Fleck. A scholar is included among the top collaborators of P. Fleck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Fleck. P. Fleck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
White, William B., Stuart Kupfer, Steven Nissen, et al.. (2014). CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL. Journal of the American College of Cardiology. 63(12). A116–A116. 6 indexed citations
4.
Bron, Morgan, Craig Wilson, & P. Fleck. (2014). A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. Diabetes Therapy. 5(2). 521–534. 7 indexed citations
5.
Raalte, Daniël H. van, Renate E. van Genugten, Björn Eliasson, et al.. (2014). The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. European Journal of Endocrinology. 170(4). 565–574. 38 indexed citations
6.
Zannad, Faı̈ez, Christopher P. Cannon, William C. Cushman, et al.. (2014). ALOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES AFTER ACUTE CORONARY SYNDROMES: HEART FAILURE OUTCOMES AND CARDIOVASCULAR SAFETY IN HEART FAILURE PATIENTS. Journal of the American College of Cardiology. 63(12). A117–A117. 12 indexed citations
7.
White, William B., Christopher P. Cannon, Simon Heller, et al.. (2013). Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 369(14). 1327–1335. 1857 indexed citations breakdown →
8.
Eliasson, Björn, Diane L. Möller-Goede, Katarina Eeg‐Olofsson, et al.. (2012). Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 55(4). 915–925. 75 indexed citations
9.
DeFronzo, Ralph A., Charles Burant, P. Fleck, et al.. (2012). Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 97(5). 1615–1622. 87 indexed citations
10.
11.
White, William B., George L. Bakris, Richard M. Bergenstal, et al.. (2011). EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). American Heart Journal. 162(4). 620–626.e1. 128 indexed citations
12.
Rosenstock, Julio, Silvio E. Inzucchi, Jochen Seufert, et al.. (2010). Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes. Diabetes Care. 33(11). 2406–2408. 102 indexed citations
13.
Karim, Aziz, Aziz Laurent, Melvin Munsaka, et al.. (2009). Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants. The Journal of Clinical Pharmacology. 49(10). 1210–1219. 34 indexed citations
14.
Pratley, Richard E., et al.. (2008). Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obesity and Metabolism. 11(2). 167–176. 143 indexed citations
15.
16.
Christopher, Ronald, Paul S. Covington, Miles P. Davenport, et al.. (2008). Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clinical Therapeutics. 30(3). 513–527. 106 indexed citations
17.
18.
Miller, Carole B., Edmund K. Waller, Hans-G. Klingemann, et al.. (2004). Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplantation. 33(5). 543–548. 24 indexed citations
19.
First, M. Roy, P Weiskittel, Malay B. Shah, et al.. (1998). Conversion of stable renal transplant recipients from sandimmune to sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. Transplantation Proceedings. 30(5). 1701–1705. 4 indexed citations
20.
Martin, Jill, P. Fleck, T J Schroeder, J Whiting, & Douglas W. Hanto. (1998). The Cost of Rejection in Liver Allograft Recipients. Transplantation Proceedings. 30(4). 1500–1501. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter P. Stein Breakdown of academic impact, for papers by Hans‐Juergen Woerle Breakdown of academic impact, for papers by Peter Öhman Breakdown of academic impact, for papers by M. Angelyn Bethel Breakdown of academic impact, for papers by Craig Wilson Breakdown of academic impact, for papers by Alfonso T. Perez Breakdown of academic impact, for papers by Jennifer B. Green Breakdown of academic impact, for papers by Matthew A. Cavender Breakdown of academic impact, for papers by Stuart Kupfer Breakdown of academic impact, for papers by Richard M. Bergenstal
Rankless by CCL
2026